All terms in GO

Label Id Description
B cell anergy GO_0002515 [Any process contributing to anergy in B cells, a state of functional inactivation which is part of B cell tolerance induction.]
B cell receptor editing GO_0002452 [The process of replacing receptors on B cells, in which RAG gene expression allows continued light-chain gene rearrangement and expression of a new light change which combines with the previous heavy chain to form a new receptor.]
somatic recombination of immunoglobulin gene segments GO_0016447 [The process in which immunoglobulin genes are formed through recombination of the germline genetic elements, as known as immunoglobulin gene segments, within a single locus.]
peripheral B cell tolerance induction GO_0002451 [Tolerance induction of mature B cells in the peripheral lymphoid tissues: the blood, lymph nodes, spleen, and mucosal-associated lymphoid tissue.]
B cell tolerance induction GO_0002514 [A process involving any mechanism for tolerance induction in B cells.]
B cell antigen processing and presentation GO_0002450 [The process in which a B cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex.]
eosinophil mediated immunity GO_0002447 [Any process involved in the carrying out of an immune response by an eosinophil.]
chronic inflammatory response to antigenic stimulus GO_0002439 [A chronic inflammatory response to an antigenic stimulus. A chronic inflammatory response persists indefinitely during days, weeks, or months in the life of an individual.]
immune complex clearance by monocytes and macrophages GO_0002436 [The process of immune complex clearance by monocytes or macrophages.]
immune complex clearance GO_0002434 [A process directed at removing immune complexes from the body. Immune complexes are clusters of antibodies bound to antigen, to which complement may also be fixed, and which may precipitate or remain in solution.]
immune complex clearance by erythrocytes GO_0002435 [The process of immune complex clearance by erythrocytes. The process often starts with binding of complement receptor 1 (CR1) on the surface of erythrocytes to a complement coated immune complex. The complex bound to erythrocyte CR1 is then transported to the liver or spleen where it is presented to phagocytes. The process ends when the complex is removed from CR1, allowing the erythrocyte to return to general circulation.]
granuloma formation GO_0002432 [The formation of nodular inflammatory lesions, usually small or granular, firm, persistent, well-structured, and containing compactly grouped T lymphocytes and modified phagocytes such as epithelioid cells, giant cells, and other macrophages. Granuloma formation represents a chronic inflammatory response initiated by various infectious and noninfectious agents. The center of a granuloma consists of fused macrophages, which can become necrotic.]
mucosal tolerance induction GO_0002427 [Tolerance induction taking place in the mucosal tissues.]
mucosal immune response GO_0002385 [An immune response taking place in mucosal tissues, including those of the intestinal tract, nasal and upper respiratory tract, and genital tract.]
immunoglobulin production in mucosal tissue GO_0002426 [The synthesis and release of immunoglobulin in the mucosal tissue.]
immunoglobulin production involved in immunoglobulin-mediated immune response GO_0002381 [The appearance of immunoglobulin due to biosynthesis or secretion following a cellular stimulus during an immune response, resulting in an increase in its intracellular or extracellular levels.]
tolerance induction in urogenital tract GO_0002425 [Tolerance induction taking place in the urogenital tract.]
T cell mediated immune response to tumor cell GO_0002424 [An immune response mediated by a T cell triggered in response to the presence of a tumor cell.]
immune response to tumor cell GO_0002418 [An immune system process that functions in the response of an organism to a tumor cell.]
natural killer cell mediated immune response to tumor cell GO_0002423 [An immune response mediated by a natural killer cell triggered in response to the presence of a tumor cell.]